title: Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.
abstract: BACKGROUND
  There are known to be wide differences in the prognosis of patients with a diagnosis of AIDS. In this study of 6578 patients with AIDS form 17 European centres, we develop a ranking of AIDS-defining illnesses, and determine how well this ranking holds after adjustment for potential confounding variables.
  
  
  METHODS
  Survival from each AIDS-defining event was calculated and ranked using Kaplan-Meier estimation of median survival. Cox proportional hazards models with each disease modelled as a time dependant covariate were used to determine the risk of death after each diagnosis, before and after adjustment for potential confounders.
  
  
  RESULTS
  Median survival after an initial AIDS-defining diagnosis of progressive multifocal leukoencephalopathy and malignant lymphoma was particularly poor (2 and 5 months respectively), while the longest median survival occurred after initial AIDS-defining illnesses of Kaposi's sarcoma and extrapulmonary tuberculosis (17 and 22 months respectively) Patients diagnosed with a primary brain lymphoma had shorter median survival times than patients with a peripheral lymphoma (median survival of 1 month and 4 months respectively P < 0.0001). In general, median survival in patients with cutaneous Kaposi's sarcoma (skin, oral) was between two and four times longer than patients with systemic involvement The ranking of diseases was found to be generally similar after adjustment for all potential confounders.
  
  
  CONCLUSIONS
  AIDS-defining events can be grouped into three categories with median survival after diagnosis of < 6 months. 6-12 months and > 12 months. The assigned ranking of disease would not be altered by prognostic factors such as age or CD4 lymphocyte count. These results have important implications in the design of clinical trials and patient management.
authors.affiliation: Dept Primary Care and Population Sciences, Royal Free Hospital School of Medicine, London, UK.
authors.forename: A J
authors.initials: AJ
authors.lastname: Mocroft
authors.forename: J D
authors.initials: JD
authors.lastname: Lundgren
authors.forename: A
authors.initials: A
authors.lastname: d'Armino Monforte
authors.forename: B
authors.initials: B
authors.lastname: Ledergerber
authors.forename: S E
authors.initials: SE
authors.lastname: Barton
authors.forename: S
authors.initials: S
authors.lastname: Vella
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.forename: J
authors.initials: J
authors.lastname: Gerstoft
authors.forename: C
authors.initials: C
authors.lastname: Pedersen
authors.forename: A N
authors.initials: AN
authors.lastname: Phillips
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000401:mortality*; D000163:Acquired Immunodeficiency Syndrome / Q000401:mortality*; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000401:mortality*; D016019:Survival Analysis; D015996:Survival Rate